270 related articles for article (PubMed ID: 29444910)
21. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
[TBL] [Abstract][Full Text] [Related]
22. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract][Full Text] [Related]
23. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract][Full Text] [Related]
24. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
25. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
[TBL] [Abstract][Full Text] [Related]
26. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
27. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
28. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Barazeghi E; Hellman P; Norlén O; Westin G; Stålberg P
Sci Rep; 2021 Nov; 11(1):22733. PubMed ID: 34815475
[TBL] [Abstract][Full Text] [Related]
29. Exome Sequencing and CNV Analysis on Chromosome 18 in Small Intestinal Neuroendocrine Tumors: Ruling Out a Suspect?
Delgado Verdugo A; Crona J; Maharjan R; Hellman P; Westin G; Björklund P
Horm Metab Res; 2015 Jun; 47(6):452-5. PubMed ID: 25354328
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
[TBL] [Abstract][Full Text] [Related]
32. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Alors-Perez E; Pedraza-Arevalo S; Serrano-Blanch R; Martínez-Fuentes AJ; Gálvez-Moreno MA; Castaño JP; Luque RM
Clin Transl Gastroenterol; 2018 Oct; 9(10):196. PubMed ID: 30297816
[TBL] [Abstract][Full Text] [Related]
33. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
34. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
[TBL] [Abstract][Full Text] [Related]
35. Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma.
Wen KW; Grenert JP; Joseph NM; Shafizadeh N; Huang A; Hosseini M; Kakar S
Hum Pathol; 2018 Jul; 77():166-174. PubMed ID: 29634977
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.
Pareja F; Vahdatinia M; Marchio C; Lee SSK; Da Cruz Paula A; Derakhshan F; da Silva EM; Selenica P; Dopeso H; Chandarlapaty S; Wen HY; Vincent-Salomon A; Brogi E; Weigelt B; Reis-Filho JS
J Clin Pathol; 2022 Jan; 75(1):10-17. PubMed ID: 33148628
[TBL] [Abstract][Full Text] [Related]
37. Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.
Ungefroren H; Künstner A; Busch H; Franzenburg S; Luley K; Viol F; Schrader J; Konukiewitz B; Wellner UF; Meyhöfer SM; Keck T; Marquardt JU; Lehnert H
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555512
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931
[TBL] [Abstract][Full Text] [Related]
39. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]